title: [Eight years of experience in a single institution in hematopoietic stem cell autologous transplantation in malignant hematological diseases and in solid tumors].
abstract: Between August 1991 and December 1998, 400 patients (lymphomas: 197; acute leukemia: 86; multiple myeloma: 70 and solid tumors: 47) were admitted for autologous transplantation. All patients were mobilized with chemotherapy plus G-CSF. The hematological recovery was similar in all disease groups. Patients with acute leukemias and multiple myeloma had a slower platelet recovery. Treatment-related death was 4.5%. The status of the disease at diagnosis was the most significant prognostic factor. With a median follow-up of 23 months the probability of event-free survival at 60 months was 46% for low grade lymphoma, 44% for intermediate and high grade lymphoma, 58% for Hodgkin's disease, 45% for acute myeloblastic leukemia, 38% for solid tumors and 15% for multiple myeloma. The probability of survival at 60 months was 67% for low grade lymphoma, 47% for intermediate and high grade lymphoma, 75% for Hodgkin's disease, 52% for acute myeloblastic leukemia, 54% for solid tumors and 25% for multiple myeloma. It can be concluded that autologous progenitor cell transplantation induces a complete and faster hematological recovery in all groups of patients without any late graft failure. Results are similar to those published in the literature. The treatment-related death was low and acceptable.
authors.affiliation: FUNDALEU, Centro de Internación e Investigación Clínica Angélica Ocampo, Buenos Aires.
authors.forename: G A
authors.initials: GA
authors.lastname: Milone
authors.forename: J
authors.initials: J
authors.lastname: Martínez Rolón
authors.forename: I I
authors.initials: II
authors.lastname: Fernández
authors.forename: C S
authors.initials: CS
authors.lastname: Corrado
authors.forename: P M
authors.initials: PM
authors.lastname: Desmery
authors.forename: M C
authors.initials: MC
authors.lastname: Dignani
authors.forename: M
authors.initials: M
authors.lastname: Juni
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D015397:Program Evaluation; D014182:Transplantation, Autologous; D016896:Treatment Outcome